



Cancer Cure Coalition

Because Patients Should Know the Treatment Options

What Can Be Done When Prostate Cancer Recurs?
A National Conference on New and Emerging Treatment Options
February 12, 2005
PGA National Resort, Palm Beach Gardens, FL

Presented in association with the Jupiter and Wellington Prostate
Cancer Support Groups



Cancer Cure Coalition

Conference Program for

What Can Be Done When Prostate Cancer Recurs?
A National Conference on New and Emerging Treatment Options
February 12, 2005
PGA National Resort, Palm Beach Gardens, FL

(Titles of presentations are working titles and this document is not for public distribution.)

- Dr. Aaron Katz, Columbia University: “The Progression of Prostate Cancer from Diagnosis to Treatment, and Remission to Relapse”
- Dr. Anna Ferrari, New York University: “Strategies to Prevent Progression of Hormone Refractory Prostate Cancer”
- Dr. Balakrishna Lokeshwar, Univ. Of Miami: “Seeking a Cure in Nature’s Pharmacy”
- Dr. George Suarez, Medical Director, USHIFU: “High Intensity Focused Ultrasound (HIFU) and other Salvage Therapies as Treatment Options for Recurrent Prostate Cancer”
- Dr. Thomas Schuetz, Medical Director, Therion: “How Vaccines Can Help Cure Prostate Cancer”

All speakers to participate in a PANEL DISCUSSION after the individual presentations are made. 

Dr. Aaron Katz

Dr. Aaron E. Katz is currently an Associate Professor of Clinical Urology at Columbia University College of Physicians & Surgeons where he has been a faculty member since 1993. He is also the Director for the Center of Holistic Urology

Dr. Aaron E. Katz also holds a title as the Director of The Center for Holistic Urology, a center that he established in 1998. The Center performs basic research and conducts clinical trials that investigate the role of natural therapies within the area of Urological Oncology. He serves on the AUA Committee of Alternative and Complementary Medicine and is the Director for Quality Assurance within the Department of Urology at Columbia_University Medical Center.


After graduating from New York Medical College in 1986, Dr. Katz completed a 6-year training program in Brooklyn at the Maimonides Medical Center. Following the completion of his residency, Dr. Katz was awarded a Ferdinand Valentine Fellowship from the New York Academy of Medicine to further his studies in Urologic Oncology at the Columbia-Presbyterian Medical Center. During his Fellowship, Dr. Katz developed a novel blood test, which could detect small numbers of prostate cancer cells in the blood. The test, known as RT-PCR (Reverse

Transcriptase Polymerase Chain Reaction), was the first time urologic cancers were staged using a molecular assay.

Dr. Katz is also recognized as an expert in the field of prostate cryosurgery. In the early 1990's, he began using cryosurgery to cure prostate cancers. His pioneer work in advancing the technology helped Medicare to approve this therapy for treating radiation-recurrent tumors.

Dr. Katz has trained nearly 100 urologists in the United States and Europe to perform cryosurgery in their hospitals. Dr. Katz has also applied cryosurgery to the treatment of small kidney tumors.

To date, Dr. Katz has published over 60 scientific articles in peer-reviewed journals, and has written 4 chapters for Urologic textbooks. He has been the host of a radio program called "Men's Health Talk" in New York City for the past year. In addition, he has lectured throughout the United States, Europe, and Japan.


Dr. Katz has an office at the Columbia-Presbyterian Medical Center, as well as in Midtown Manhattan. He is a member of the Scientific Advisory Board of the Cancer Cure Coalition. 

Dr. Balakrishna Lokeshwar


Dr. Bal Lokeshwar, Ph.D. is a tenured Associate Professor of Urology at the University of Miami School of Medicine, and holds a joint appointment in the Department of Radiation Oncology. Lokeshwar received a combined Bachelors and Masters of Science degree in biological sciences from Birla Institute of Technology in Pilani, India. He received his Ph.D. degree from the Department of Microbiology and Cell Biology at the Indian Institute of Science. He did postdoctoral training in Biochemistry and Molecular Biology in the United States at St. Louis University, and later joined the Department of Radiation Oncology at Washington University School of Medicine. From that time on he decided to focus his scientific research to cancer.

Since joining the University of Miami/Sylvester Cancer Center, Dr. Lokeshwar's research has focused on the mechanism of prostate cancer metastasis and its control by novel chemotherapeutic drugs. For the last several years, research in his laboratory has focused on extracellular matrix degradation and tumor metastasis. His group has been studying the regulation of a class of basement membrane matrix degrading enzymes called the matrix metalloproteinases (MMPs) in prostate cancer. This line of research has shown that there exists an imbalance between the levels of MMPs (overproduction) and their

natural inhibitors (under production) in invasive prostate cancer cells. Another research focus is an emphasis on chemo-prevention using 1,25-alpha-dihydroxy vitamin D, the hormonal form of Vitamin D. He has also identified a novel chemically modified non-antimicrobial tetracycline (COL-3) that works as an effective anti-metastatic drug with potential to treat prostate cancer metastatic to bone. The National Cancer Institute has completed the Phase I trial of this drug and is awaiting further trials. The drug under the name COL-3 is currently under Phase III clinical trial at multiple medical centers as a potential treatment for AIDS related Kaposi's sarcoma and other malignancies. Other novel agents are being tested in Dr. Lokeshwar's laboratory not only for controlling cancer but also other chronic diseases such as chronic ocular surface inflammation. Dr. Lokeshwar's research has brought in three patents to the University of Miami, two shared with the State University of New York at Stony Brook.

He is honored to have been a member of the Scientific Advisory Board of the Cancer Cure Coalition and looks forward to working with the other members of its team to help educate the public about new and less toxic treatments for cancer, as well as the role of nutrition in helping to prevent the development of disease. 

Dr. Joseph P. Crawford, M.D., F.A.C.S.


Dr. Joseph Crawford is a graduate of the Ohio State University and the University of Maryland School of Medicine. He completed his internship and surgical and urological residencies at the Medical College of Virginia in Richmond. He also completed a national bladder cancer group fellowship at the same institution. In 1985, we entered in private urologic practice on Florida's Treasure Coast specializing in urologic oncology, impotence, incontinence, and prostatic diseases. Dr. Crawford currently serves as the President of Treasure Coast Urology as well as Indian River Physicians Associates in Vero Beach. Treasure Coast Urology currently is one of the country's foremost centers for excellence in cryosurgical treatment of urologic malignancies, specializing in prostate and kidney cancer treatment. Dr. Crawford is certified by the American board, has current certification by the American Board of Urology, and is a fellow of the American College of Surgeons. 



Dr. Craig Berman M.D.

Craig Berman, M.D. is a urologic oncologist. He received a B.S in Chemistry from Northwestern University, and completed graduate work in biochemistry at the Weizsman Institute in Israel. He obtained his medical degree at the University of Colorado and completed a urology residency at the University of Iowa. He obtained fellowship training in urological oncology at the University of Colorado.

His research in cancer has included the study of the mechanism by which histones interact with DNA and how to chemically disrupt this process. He has also studied the use of adenovirus vectors to deliver a toxic gene (herpes thymidine kinase) to prostate cancer. Currently, he is working with Cell Genesys, Inc. on a Phase 3 trial of an allogeneic prostate cancer vaccine for use in hormone refractory prostate cancer.

Cell Genesys, Inc. is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is conducting clinical trials in multiple types of cancer utilizing two different product platform technologies, the GVAX[®] cancer vaccines and oncolytic adenovirus therapies. 

The Cancer Cure Coalition wishes to thank the following for their generous support for this conference

■ Corporate Sponsors

Natural Source Ltd.
New Chapter
Endocare & Treasure Coast Urology

■ Corporate donors

Enterprise National Bank
Jupiter Medical Center
Wellington Medical Center
Merrill Lynch
AstroZenca

■ Individual donors

Charles and Anne Reinwald
Don and Barbara Raskin
Jesse and Joyce Seligman
Paul and Linda Loschiavo

The Cancer Cure Coalition produced this conference with the hard work and support of the following:

■ Conference Committee

Bram H. Levin, Chair
Don Raskin, Finance
David Most
Charles A. Reinwald
Jesse Seligman

■ Conference Staff & Volunteers of the Cancer Cure Coalition

Lela Graham, Scientific Consultant
Dottie Levin, Volunteer
Michael Levin, Communications Consultant
Charles Reinwald, Jr., VP, Board of Directors
Martha Suarez, Volunteer
?????????????, Volunteer

■ We also wish to acknowledge the helpfulness of

Crystal Dillard, Jupiter Medical Center
Mike Shea, Treasure Coast Urology
Jackie Hibbs, Endocare
Cheryl Metzger, Natural Source
Melinda Walsh, New Chapter
Cell Genesys
USHIFU
PGA National Resort
Fade2Black Productions
Merrill Lynch Jupiter Office
Estrada, AstraZeneca